GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 25,459 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 25,459 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total transaction of $2,001,331.99. Following the transaction, the chief executive officer directly owned 38,683 shares in the company, valued at $3,040,870.63. This represents a 39.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The stock was sold at an average price of $94.00, for a total value of $155,382.00.
• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The shares were sold at an average price of $143.89, for a total value of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total value of $579,619.92.

GeneDx Price Performance

Shares of NASDAQ WGS traded up $4.09 during mid-day trading on Friday, reaching $86.09. The company had a trading volume of 247,880 shares, compared to its average volume of 764,528. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -114.79 and a beta of 2.03. The business’s 50-day simple moving average is $101.71 and its 200 day simple moving average is $122.42. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. On average, research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on WGS shares. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Canaccord Genuity Group upped their price objective on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price for the company in a research note on Monday, February 9th. Finally, Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $150.71.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated purchase: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, signaling institutional/insider confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director purchases: Director Keith A. Meister made two recent buys — 140,026 shares on Mar 5 at ~$81.19 (~$11.37M) and 29,495 shares on Mar 3 at ~$70.89 (~$2.09M) — increasing his stake to over 3.2M shares. Large insider buys by a director typically signal confidence and can spur investor demand. SEC ownership filing — Keith A. Meister purchases
• Neutral Sentiment: Short-interest data shows 0 reported short interest as of Mar 5 (days-to-cover 0.0), which appears to be a data anomaly or non-material reading; it provides little actionable signal for directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 at an average ~$78.61 (~$2.00M), reducing her direct ownership by ~39.7%. Significant insider sales can prompt investor concern about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 at the same avg price (~$78.61) for ~ $486k, trimming his stake by ~24.9%. Smaller than the institutional buys but adds to mixed insider signals. SEC Form 4 — CFO sale

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in GeneDx by 42.7% during the 2nd quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock worth $2,549,000 after acquiring an additional 8,258 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of GeneDx by 340.4% during the third quarter. Principal Financial Group Inc. now owns 59,624 shares of the company’s stock valued at $6,424,000 after acquiring an additional 46,085 shares during the last quarter. ARK Investment Management LLC acquired a new position in shares of GeneDx during the third quarter worth $48,157,000. Impax Asset Management Group plc bought a new stake in shares of GeneDx in the third quarter worth $5,387,000. Finally, Legal & General Group Plc increased its holdings in GeneDx by 55.9% in the second quarter. Legal & General Group Plc now owns 22,271 shares of the company’s stock valued at $2,056,000 after purchasing an additional 7,987 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.